Teva Will Rebut Latest EU Competition Criticism
Supplementary Statement Of Objections Issued By Commission Over Modafinil
Executive Summary
In the wake of the European Commission issuing Teva with a supplementary statement of objections over a historical “pay for delay” patent settlement agreement on modafinil with Cephalon, the Israeli firm has insisted on its right to reply.
You may also be interested in...
CJEU Opinion Backs Lundbeck Fine Over Citalopram ‘Pay For Delay’ Deals
A CJEU advocate general has backed a European Commission fine of almost €94m imposed on Lundbeck over “pay for delay” deals struck with four generics firms over citalopram.
Patent Settlements May Break EU Law
Patent-litigation settlements reached almost 20 years ago in the UK over GSK’s Seroxat paroxetine antidepressant may contravene EU competition law, an advocate general has advised the CJEU.
What Teva's $1.2bn settlement means for pay for delay
Drug manufacturer giant Teva was practically at the courthouse steps when it settled on 28 May for $1.2bn with the US Federal Trade Commission (FTC) over what the agency said were illegal efforts by the company's subsidiary Cephalon to block US generic competition of its $1bn blockbuster narcolepsy and sleep apnea drug Provigil (modafinil).